PATENT CLAIM ANALYSIS

Application Number: 16045358
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["544", "281000"]

Abstract:
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Claim (Index 87):
The method of  claim 85 , wherein the diffuse large B cell lymphoma is activated B-cell like (ABC) diffuse large B cell lymphoma, or germinal center B cell (GCB) diffuse large B cell lymphoma.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.27778
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15343375', '15631417', '13085643', '13329532', '14872881']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8327271829151427
- 35 USC 102 Novelty (BERT): 0.5750334741403521
- Combined Prediction Score: 0.8069578120376636
- Mean Citation Score: 421.74511
- Max Citation Score: 495.84445
- Similarity Product: 254.738646285814

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test